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Abstract
Plasmacytoid Dendritic Cells (pDCs) represent a key immune cell in the defense against viruses. Through pattern recognition
receptors (PRRs), these cells detect viral pathogen associated molecular patterns (PAMPs) and initiate an Interferon (IFN)
response. pDCs produce the antiviral IFNs including the well-studied Type I and the more recently described Type III. Recent
genome wide association studies (GWAS) have implicated Type III IFNs in HCV clearance. We examined the IFN response
induced in a pDC cell line and ex vivo human pDCs by a region of the HCV genome referred to as the HCV PAMP. This RNA
has been shown previously to be immunogenic in hepatocytes, whereas the conserved X-region RNA is not. We show that
in response to the HCV PAMP, pDC-GEN2.2 cells upregulate and secrete Type III (in addition to Type I) IFNs and upregulate
PRR genes and proteins. We also demonstrate that the recognition of this RNA is dependent on RIG-I-like Receptors (RLRs)
and Toll-like Receptors (TLRs), challenging the dogma that RLRs are dispensable in pDCs. The IFNs produced by these cells
in response to the HCV PAMP also control HCV replication in vitro. These data are recapitulated in ex vivo pDCs isolated from
healthy donors. Together, our data shows that pDCs respond robustly to HCV RNA to make Type III Interferons that control
viral replication. This may represent a novel therapeutic strategy for the treatment of HCV.
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Introduction
Pathogens are sensed by host pattern recognition receptors
(PRR) that recognize molecular motifs. Two major receptor
systems sense the presence of viral infection to mount an immune
response: toll-like receptors (TLRs) 3, 7, 8, and 9 are major PRRs
that respond to different types of viral nucleic acids, and more
recently, retinoic acid inducible gene-I (RIG-I)-like receptors
(RLRs), helicases including RIG-I and MDA-5 (melanoma
differentiation-associated gene 5), have been identified as cytosolic
receptors for intracellular dsRNA sensing [1,2]. The relative
contributions of TLRs and RLRs as viral sensors vary according to
viruses and across different cell types [1]. By specializing in the
production of Type I Interferons (IFNs), i.e. IFN-a and IFN-b,
plasmacytoid DCs (pDCs) play crucial roles as mediators of
antiviral responses [3,4]. RIG-I signaling has been described as
largely dispensable for pDC secretion of IFN-a following infection
with RNA viruses [1], whereas the TLR system is critical for the
RNA virus-mediated IFN response in pDC [5].
Affecting an estimated 200 million people globally, hepatitis C
virus (HCV) is the world’s most common blood-borne viral
infection for which there is no vaccine [6]. The majority of
individuals exposed to this RNA virus will develop viral
persistence; however, there are significant differences in how
patients respond to HCV infection and its treatment [7]. HCV
infection has been associated with depletion and functional
suppression of pDCs [8,9]. Some studies have shown that pDCs
from the blood of patients with chronic HCV are infected [10],
whereas others have failed to demonstrate viral infection within
the pDCs. Moreover, some viruses can activate pDCs to produce
Type I IFN without the need for active replication [4,11]. Direct
contact with HCV-infected hepatocytes induces Type I IFN via
TLR7 signaling within pDCs [12]. Furthermore, Chisari’s group
has demonstrated that HCV RNA is transferred to the pDCS from
hepatocytes via a non-endocytic mechanism [13].
Although their receptor subunits do not display any detectable
homology, Type III IFNs are functionally similar to Type I IFNs,
signaling through JAK-STAT intracellular pathways and upregu-
lating the transcription of IFN-stimulated genes (ISGs) required to
control viral infection [7]. Recently, considerable data have linked
genetic variation within or near the Type III IFN-l3 (IL-28B) gene
with HCV recovery [14,15]. In this study, for the first time, we
define the consequences of human pDC sensing of the HCV
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genome 39 non-translated poly-U/UC tract, previously shown to
function as the HCV pathogen-associated molecular pattern
(PAMP) [16] substrate of cytosolic RIG-I. Extensive analysis and
characterization of the HCV genomic RNA has identified that the
pU/UC tract in the 39 UTR had the greatest capacity to stimulate
IFN-b production in hepatocytes [16]. We hypothesized and now
show that the HCV PAMP triggers robust and varied IFN
responses from the human pDC cell line GEN2.2 and the secreted
Type III IFNs inhibit viral replication. We demonstrate that
neutralization of Type III IFNs (IFN- l) attenuates the anti-HCV
effects of pDC-GEN2.2-derived supernatants. Addition of pDC-
derived supernatants activates the JAK/STAT pathway in the
Huh7.5.1 hepatoma cell line. Furthermore, we demonstrate that
laboratory-determined concentrations of Type III IFNs inhibit
viral replication. Finally, we recapitulate the induction of Type III
Interferons following recognition of the pU/UC RNA in freshly-
isolated ex vivo human pDCs and show their capacity to inhibit
replication.
Results
GEN2.2 pDC cell line resembles circulating blood pDCs
Due to the extremely low frequency of pDCs circulating in
normal healthy adults [8], we used the GEN2.2 pDC cell line
(pDC-GEN2.2) [17] that phenotypically expresses classic
markers of pDCs, as well as various other surface markers
relevant to co-stimulation (Figure 1). Because our focus was to
understand HCV pathobiology, we cultured the pDC-GEN2.2
using the human hepatoma cell line Huh7.5.1 (known to
support HCV replication) as the feeder cells. For all of our
single-cell experiments using the pDC-GEN2.2 cell line, we used
the non-adherent fraction of the cultures. Using only the non-
adherent fraction from these cultures, we determined that the
cells were over 95% BDCA-2+ and CD45+ thus indicating that
the feeder line did not contaminate the cell fraction used for
experiments. We felt that using a human hepatic cell line as
feeders would make our system more relevant to the study of
HCV. The cells were positive for Blood Dendritic Cell Antigen
(BDCA)-2 (Cluster of Differentiation [CD] 303), HLA-DR and
CD123, markers of pDCs, but were negative for CD11c,
BDCA-1 and BDCA-3, typical markers of myeloid DCs. Of the
non-adherent cells, over 95% were BDCA-2, HLA-DR double
positive. While there is the possibility of contamination from the
adherent Huh7.5.1 feeder cells, we feel that this contamination
would be minor and not affect the overall results of our studies.
Additional characterization of the non-adherent cells showed
that these cells expressed CD86, CD44 and CD119 (IFNcR)
with low levels of CD80, CD83, CD209 (DC-SIGN) and
IFNaR1. TLR2 and TLR7 mRNA was consistently detected,
and TLR3 and TLR9 protein levels were demonstrable by flow
cytometry. The cells showed a round, even morphology as
expected from suspended dendritic cells (Figure 1D). The
absence of other morphologies within our microscopic samples
provides evidence that the non-adherent fraction of our cultures
consist primarily of the pDC-GEN2.2 cells. Additionally, we
genotyped the cell line for an IL-28B SNP (IFN- l3;
rs12979860) that is associated with HCV clearance [14,15]
and a RIG-I SNP (rs10813831) that has been associated with
differential trends in IFNb1 production [18]. In the case of the
IL-28B SNP, the genotype associated with HCV clearance is the
CC homozygous allele [14,15] and was identified as the
genotype present in the pDC-GEN2.2 cell line. The RIG-I
SNP is an amino acid change (genotype G to A; Arg to Cys) in
the protein sequence of RIG-I [18]. Patients with the rare
homozygous AA genotype demonstrated a trend of higher RIG-
I and IFNb1 expression levels [18]. The pDC-GEN2.2 cell line
was determined to have the AA genotype for this RIG-I SNP.
Given the characterization, we concluded that these cells were a
reasonable proxy of pDCs for our in vitro experiments.
Robust Type I and III Interferon production following TLR
ligation in pDCs
We investigated the profile of IFN transcripts following
stimulation with viral TLR ligands in vitro. pDCs recognize RNA
and DNA viruses through two endosomal sensors, TLR 7 and
TLR9, respectively, that induce Type I IFN secretion through the
Myeloid differentiation primary response gene (MyD88)-Interfer-
on regulatory factor 7 (IRF7) signaling pathway [4]. By examining
the mRNA levels of IFN genes after 6 hours of co-culture with
poly I:C (TLR3), Loxiribine (TLR7/8), and Oligodeoxynucleotide
(ODN) 2216 (Type A CpG molecule, TLR9 ligand), we
characterized ability of the pDC-GEN2.2 cell line to respond to
a variety of viral stimulants. As shown in Figure 2, there was
significant induction of IFNa1, IFNa2, IFNb1, IL-28A (IFNl2),
and IL-29 (IFNl1). Not surprisingly, combined TLR3 and TLR7/
8 ligation induced the most robust induction of interferon genes
given that transcripts for TLR7 were consistently present.
Additionally, we found up-regulation of RIG-I, TLR2 and
TLR8 mRNA within the pDC-GEN2.2s. Next, we wanted to
determine whether a feedback loop of Type I IFN contributed to
these IFN expression patterns. To understand how these cells
respond to IFNa2 stimulation, we co-cultured the cells with
pegylated-Interferon-a2 (commonly used in HCV therapy [19]
along with the purine analog ribavirin) for 6 hours and then
examined the IFN responses by qRT-PCR. Compared to
stimulation with viral TLR ligands, Type I and III IFN showed
relatively diminished or absent transcriptional effect, indicating
that the response seen after stimulation with viral TLR ligands is
not solely attributable to an IFNa2 feedback mechanism (Figure
S1).
Author Summary
Hepatitis C Virus (HCV) is the most common bloodborne
pathogen for which no vaccine is available. Infection with
the virus often leads to persistent (or chronic) infection.
Patients with chronic HCV infection can develop progres-
sive liver disease and liver failure, leading to the need for a
transplant. It is not fully understood why some people
clear the virus and others develop persistent infection.
Understanding differences in how patients respond to the
virus in the early phases of infection may lead to better
treatment of HCV. Here, we use a highly conserved region
of the HCV genome to examine innate immunological
responses to HCV. We found that plasmacytoid dendritic
cells, innate cells keyed to respond with anti-viral
interferon proteins, recognize the virus. Additionally, we
show that pDCs use RIG-I in the recognition of this virus,
which was previously thought to be dispensable in pDCs.
The proteins secreted by these cells can control viral
replication in a cell-based laboratory system. In cells
isolated from healthy donors, we found that fresh human
cells can respond in the same manner to the virus as the
laboratory strain of cells, and there was a correlation with
genetic differences. Our study offers novel insight to how
the body recognizes HCV during early infection and host-
virus interactions that mediate viral control of this
common infection.
Human pDCs Produce IFN-ls against HCV RNA
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pDCs sense HCV PAMP and produce Type I and Type III IFNs
The poly-U/UC (pU/UC) tract of the HCV genome 39 non-
translated region functions as the PAMP substrate of retinoic acid-
inducible gene (RIG-I), the cytosolic PRR for HCV [16,20]. Of
the several regions that were tested in the Saito et al. study, this
pU/UC region was found to be the most stimulatory region [16].
The nearby X-region, a highly conserved region in the 39
untranslated region (UTR) of the HCV genome, is not immuno-
Figure 1. pDC cell line resembles ex vivo pDCs. A) Classic pDC surface phenotype. GEN2.2 cell line expresses the classic markers of ex vivo
human pDCs: CD45+ HLA-DR+ BDCA-2+ CD123+ CD11c2 BDCA-12 BDCA-32 (representative flow plots from 3 independent experiments). B) GEN2.2
cell line expresses intracellular TLR3 and TLR9. C) GEN2.2 cell line express costimulatory markers CD86 and CD44, CD119 (IFNcR) and express low
levels of CD80, CD83, CD209 (DC-SIGN) and IFNaR1. D) GEN2.2 cellular morphology; Green – b-actin, Blue - Nuclei. Scale bar is 30 mm.
doi:10.1371/journal.ppat.1003316.g001
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genic and thus was used as a negative control (Figure 3A) in these
experiments. Transfection of the pU/UC RNA into the pDC-
GEN2.2 cells, in the absence of the feeder cells, lead to
pronounced transcriptional induction of multiple IFNs
(Figure 3B), beginning as early as 2 hrs and in general, peaking
at 8 hrs, but remaining elevated after 24 hrs of transfection. The
X-region RNA did not consistently induce greater IFN production
compared to mock transfection (Figure S2B). In comparison to
the induction of IFN genes by pU/UC RNA, the IFN gene
expression induced by the X-region RNA was relatively weak
(Figure S2). The 29-59 oligoadenylate synthetases (OAS) are a
family of antiviral proteins that are induced by both virus infection
and IFN stimulation and activate latent endoribonuclease (RNase
L) [21], yielding RNA cleavage products that initiate innate
signaling [22]. HCV pU/UC RNA transfection increased OAS-1
transcription in pDC-GEN2.2 cells more than 40-fold at 8 hrs
(Figure 3C). However, RNaseL, constitutively expressed in
lymphatic tissue [23], was not further induced or upregulated by
HCV PAMP transfection (Figure S3). Furthermore, transfection
with the HCV PAMP upregulated transcriptional expression of
PRR signaling genes, in particular RIG-I (Figure 3C).
Supernatants from pDC-GEN2.2 cultures that were stimulated
with pU/UC RNA, X-region RNA or mock transfection were
assayed for levels of IFN proteins by ELISA (Figure 3 D–G). At
24 hours post transfection, high levels of all IFN proteins assayed
were observed in the pU/UC stimulated condition. The pU/UC
IFN protein levels were significantly higher than X-region IFN
protein levels for both Type I and III IFNs, in accordance with the
gene expression data (Figure 3B). The average concentrations of
IFNa, IFNb, IL-28A (IFNl2) and IL-29 (IFNl1) were 2600 pg/
mL, 650 pg/mL, 1500 pg/mL and 475 pg/mL, respectively.
IFNa, IFNb and IL-29 (IFNl1) were also detectable at 8 hours
post-transfection (data not shown). IL-28B (IFNl3) could not be
assayed by ELISA so we examined IL-28B (IFNl3) protein levels
in cell lysates from the stimulated pDC-GEN2.2 cells by Western
blot from three independent experiments. We found that IL-28B
(IFNl3) was detectable in the cell lysates of these cells and that
more IL-28B was present in the pU/UC condition than either the
mock or X-region condition (Figure 3H) although this difference
was not statistically significant.
PRR protein levels were also increased after 8 and 24 hours of
pU/UC stimulation compared to mock or X-region transfection
(Figure 3I, left). Densitometry revealed a significant increase in
protein level for RIG-I and MDA-5 after 24 hours in the pU/UC
RNA transfection compared to the X-region RNA transfection
(Figure 3I, center). MyD88 and TRIF protein levels were not
increased. The increases in protein are consistent with the gene
expression data from 8 hours where each gene showed a
significant upregulation from pU/UC stimulation compared to
the X-region stimulation with the most robust upregulation in
RIG-I and MDA-5 (Figure 3I, right). Together, these data
demonstrate that pDC-GEN2.2 cells not only respond to HCV
RNA with IFN gene expression and protein production, but the
cells also upregulate PRR genes and proteins, particularly RIG-I
which is the known cytosolic receptor for the HCV PAMP.
It has been shown previously that RIG-I requires 59 triphos-
phate groups for recognition and signaling [24]. TLR3 and TLR7
have not been shown to have the same requirement for this
biochemical feature [25]. We hypothesized that if RIG-I were
involved in the recognition and response to the HCV PAMP
RNA, removal of the 59 phosphate groups would abrogate the
production of IFN mRNA. We treated the in vitro transcribed
HCV RNA with Antarctic phosphatases and then transfected 1 mg
of the treated RNA into pDC-GEN2.2 cells. After treatment with
the phosphatases, much of the IFN mRNA production was lost.
This was true of Type I and Type III IFN message (Figure 4A).
Additionally, siRNA knockdown of RIG-I in the GEN2.2-pDCs
resulted in significantly decreased Type I and Type III IFN
message after stimulation with the pU/UC RNA compared to the
scrambled siRNA condition (Figure 4B). These findings suggest
that although TLRs have been considered the primary mode of
recognition in pDCs, RIG-I is involved in the recognition of the
HCV PAMP RNA. While much of the IFN mRNA production
was lost, there was still some production of IFN mRNA, suggesting
that in addition to RIG-I, other PRRs might be involved in the
recognition of this RNA. In particular, TLRs and RLRs may work
Figure 2. Robust Type I and III Interferon production following TLR ligation in pDC-GEN2.2 cells. Fold increases for each gene at each
condition are shown after normalization to reference gene GAPDH and are compared to stimulation of media alone (dashed line). A) Type I and Type
III IFN genes are markedly upregulated after TLR stimulation (Type II IFNc was not expressed; data not shown). The poly I:C and loxoribine combined
condition elicited the most pronounced expression, indicating a synergistic effect of TLR3 and TLR7 ligation. B) TLR stimulation induces PRR gene
upregulation, most prominently RIG-I and TLR8. p values represent the Wilcoxon signed rank result for each gene and condition as compared to
media only condition. * p,0.05+p,0.016p,0.001 # p#0.0001. Bars represent the mean and error bars are +/2 SEM.
doi:10.1371/journal.ppat.1003316.g002
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Figure 3. pDC-GEN2.2 cells sense HCV PAMP and produce Type I and Type III IFNs. A) Cartoon of the 39 end of the HCV genome indicating
the location of the poly U/UC (pU/UC, HCV PAMP) and the X-region in the 39 UTR. Adapted from reference [20]. B) Kinetics of interferon gene
upregulation in GEN2.2 cells following transfection with the pU/UC RNA. Fold increases for each gene at each condition are shown after
Human pDCs Produce IFN-ls against HCV RNA






























D 2 hours 
D 4 hours 
IZl 8 hours 
• 24 hours 




E -- 600 Ol 
0.. 
























... NP. ...... ~P.... ------ .. LaD 0,......_ __ -'-....L. NO NO o..r...--....o--.&.LoD o....,N.o,__..,.........,.-.--LoD 
Mock X-region pU/UC Mock X-region pU/UC Mock X-region pUIUC Mock X-region pU/UC 
H Mock X-region pU/UC hrs. 8 24 8 24 8 24 $2.0 ·;:: 
Mock X-region pU/UC RIG-I --- :I -e 1.5 .!! 
IL-28B - MDA5 --- Z' -~ 1.0 .. 










cooperatively to induce IFN production in pDCs where the
division of labor between the PRR systems may be dependent on
the stimulating ligand.
Control of HCV replication in JFH-1/Huh7.5.1 system
using conditioned media (CM) from HCV PAMP-
stimulated DCs
In order to test the ability of the pDC-GEN2.2 cells to control
viral replication in hepatocytes, we used the JFH-1/Huh7.5.1 in
vitro culture system [26]. Cell-free supernatants from pDC-
GEN2.2 cells that had been transfected with the pU/UC RNA
were added to Huh7.5.1 cells 24 hours after infection with the
HCV JFH-1 virus. Four days later, Huh7.5.1 cells were lysed and
the viral copy number was assayed by qRT-PCR. We found that
CM from pDC-GEN2.2 cells transfected with the pU/UC RNA
controlled viral replication better than CM from pDC-GEN2.2
cells transfected with the X-region RNA or mock-transfected
(Figure 5A). Moreover, this effect was dose-dependent. The viral
control seen with the CM was attenuated at the 1:10 dilution and
lost at the 1:100 dilution (Figure 5B). In order to identify which
signaling pathways were activated within hepatocytes following co-
culture with CM from pDC-GEN2.2 cells, we used a JAK/STAT
pathway gene expression array (Table S1). Huh7.5.1 cells were
infected for 24 hours, and then CM was added at a 1:1 dilution.
Sixteen hours after the addition of the conditioned media, we
isolated RNA and examined the gene expression using the JAK/
STAT pathway gene expression array. The time-point of 16 hours
was selected since the peak for Type I IFNs is 6 hours and the
peak for Type III IFNs was 24 hours [27]. The most up-regulated
genes were STAT1 and IRF-9 (ISGF3G), a key regulator in the
JAK/STAT pathway, and these were confirmed by individual
qRT-PCR (Figure S4).
Next, we focused on defining the relative contribution of Type
III IFNs secreted by the pDC-GEN2.2 cells to viral control. In our
model system, at the same time as the addition of the 1:1 dilution
of CM from the pDCs to the infected Huh7.5.1 cell cultures, we
added a blocking antibody against Interferon-l1/l3 (IL-29/28B)
or an isotype control antibody or the Vaccinia virus protein B18R.
Using the Vaccinia virus protein B18R, which only blocks Type I
IFNs and does not recognize IFNl [28], viral control induced by
the CM was eliminated (Figure 5C). When blocking the Type III
IFNs with the dual blocking antibody, viral control was impaired.
In the presence of CM and the isotype antibody, there was greater
than 74% viral control, and this effect was partially lost when the
dual blocking antibody was present (Figure 5D). This finding
suggests a role for Type III Interferons in the control of viral
replication. This was further confirmed by addition of recombi-
nant Type III IFNs in the absence of CM at levels comparable to
normalization to reference gene GAPDH and are compared to transfection with the X-region RNA (dashed line). Levels of IFN expression at 2 (white
bars), 4 (gray bars), 8 (hashed bars) or 24 (black bars) hours are shown for each gene. C) Kinetics of PRR genes and ISGs show upregulation by pU/UC
stimulation. Kinetics are shown as indicated in A for the IFN genes. D–G) Secretion of Type I and III IFNs by pDC-GEN2.2 cells following PAMP-
stimulation. Increased production of D) IFNa, E) IFNb, F) IL-28A/IFNl2 and G) IL-29/IFNl1 as detected by ELISA from pDC-GEN2.2 cells that have been
stimulated with HCV PAMP compared to the X-region RNA. H) Western Blot of pDC-GEN2.2 cell lysates for IL-28B/IFNl3 after 24 hours of HCV PAMP
stimulation. The antibody was specific for IL-28B/IFNl3 as it recognized low levels of recombinant IL-28B/IFNl3 (rIL-28B; 10 ng) but failed to
recognize recombinant IL-28A/IFNl2 (rIL-28A; 5 mg). I) pU/UC-stimulation increases PRR signaling proteins in accordance to gene expression data.
Western blots of listed PRR proteins after 8 or 24 hours stimulation with HCV PAMP RNA. B–C) Combined data from 5 independent experiments. D–I)
Combined data from 3 independent experiments except for the gene expression graphs which are 5 independent experiments. H–I) Representative
blots from 3 independent experiments. Densitometry shows relative density of each band after normalization to the reference protein. For gene
expression graphs, p values are the Wilcoxon signed rank result for each gene and time point compared to the X-region stimulation from the same
gene and time point. For ELISA and Densitometry graphs, p values are the Mann-Whitney result for the pU/UC condition compared to the X-region
condition. * p,0.05 ** p,0.01 *** p,0.001 # p#0.0001 Bars represent the mean and error bars are +/2 SEM.
doi:10.1371/journal.ppat.1003316.g003
Figure 4. RIG-I contributes to the recognition of the HCV PAMP RNA and is necessary for IFN gene production by GEN2.2. A) Gene
expression graphs show that, after normalization to the reference gene GAPDH and Mock transfected condition, when compared to untreated HCV
RNA, the phosphatases-treated RNA induced less interferon gene production. Data are representative graph from 3 independent experiments. Bars
represent the mean and error bars are +/2 SD. B) RIG-I was knocked down in pDC-GEN2.2 cells using siRNA and then stimulated with the pU/UC or X-
region RNA. When compared to the Scrambled siRNA condition, the RIG-I knock-down condition (mean knock-down 13% by PCR) produced
significantly less IFN mRNA. Combined data from 3 independent experiments. Bars represent the mean and error bars are +/2 SEM. p values are the
Mann-Whitney result for the scrambled siRNA condition compared to the RIG-I siRNA condition. * p,0.05 ** p,0.01 *** p,0.001 # p#0.0001.
doi:10.1371/journal.ppat.1003316.g004
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those detected within the supernatants of HCV PAMP-transfected
pDC-GEN2.2 cells (Figure 5E); all recombinant Type III IFNs
alone demonstrated viral control at these experimentally-deter-
mined concentrations.
Co-culture of GEN2.2-pDCs and infected Huh7.5.1 cells
leads to viral control and production of Interferons
In order to address the ability of the pDC-GEN2.2 cells to
respond to intact virus and infected Huh7.5.1 cells we co-cultured
the pDC-GEN2.2 cells with infected Huh7.5.1. After 24 hours of
exposure to the infected Huh7.5.1 cells, the pDC-GEN2.2 cells
had significantly upregulated Type I and Type III IFNs compared
to co-culture with uninfected Huh7.5.1 cells, represented by
IFNB1 and IL-29/IFNl1 (Figure 6A). In contrast to the HCV
PAMP stimulation, we did not see upregulation of RIG-I by PCR
(data not shown). Additionally, infected Huh7.5.1 cells were co-
cultured with pDC-GEN2.2 cells that had been transfected with
the pU/UC tract RNA and examined for HCV copy number.
While the presence of pDC-GEN2.2 cells alone did lead to a
reduction in viral copy number, co-culture with pDC-GEN2.2
cells transfected with the pU/UC tract RNA controlled virus
significantly better than pDC-GEN2.2 cells that were transfected
with the X-region RNA or mock-transfected (Figure 6B).
Primary circulating pDCs respond in a similar manner to
the HCV RNA PAMP
We wanted to confirm the effects seen in the pDC-GEN2.2 cell
line in response to the HCV PAMP in ex vivo human pDCs. To
accomplish that, we isolated pDCs from four normal healthy
donors (see Methods). We characterized the pDCs using flow
cytometry (Figure S5) and found these cells to be 95+% pure with
little contamination from natural killer cells, T cells, B cells or
Figure 5. Replicative control of HCV in JFH-1/Huh7.5.1 system with conditioned media (CM) from pU/UC-transfected pDC-GEN2.2
cells. Huh7.5.1 cells were infected for 24 hours prior to the addition of CM (A–D) or rIFNs (E) then 4 days later (5 days post-infection), cells were lysed
and examined for HCV Copy number by qRT-PCR (see methods). A) Normalized JFH-1 copy number (see methods and below for calculation) after
treatment with CM from Mock (negative; white bars)-, X-region (gray bars)- or pU/UC (dark gray bars)-stimulated pDC-GEN2.2 cells after 8 hours of
RNA stimulation. B) Dose-dependent response of viral replication control. CM from the HCV PAMP-stimulated pDC-GEN2.2 cells was added to JFH-1
infected cells at the following dilutions: 1:1 (Dark gray bars), 1:10 (gray bars) or 1:100 (white bars). C) Type I IFN dependence was determined using
the Vaccinia protein B18R which blocks Type I IFN responses. D) Blocking IL-28B/IL-29 (IFNl3/IFNl1) with a blocking, cross-reactive antibody
demonstrates dependence on Type III IFNs for a portion of the viral control. E) Recombinant Type III Interferons in the absence of CM at the same
concentrations as found in the CM (IL-28A/IFNl2: 1500 pg/mL; IL-28B/IFNl3: 10 pg/mL; IL-29/IFNl1: 500 pg/mL) were added to JFH-1 infected
Huh7.5.1 cells. Normalized HCV Copy Number is shown where the infection control condition HCV copy number is set to 1 (except panel A where the
Mock condition is set to 1) and other conditions are expressed as normalized HCV copy number compared to infection control (or compared to Mock
in panel A). Normalized HCV Copy Number = (Absolute copy number for condition/absolute copy number for infection control). Combined data from
3 (A, C and E), 5 (B, D) independent experiments p values represent the Mann-Whitney result of the comparison. * p,0.05 ** p,0.01 *** p,0.001
# p#0.0001. Bars represent the mean and error bars are +/2 SEM.
doi:10.1371/journal.ppat.1003316.g005
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monocytes. These cells also expressed low levels of the co-
stimulatory markers CD80 and CD86 but highly expressed CD44.
After stimulation with the HCV RNA in the exact same way as the
pDC-GEN2.2 cell line (1 mg of HCV PAMP RNA, either pU/UC
or X-region RNA, was transfected into the cells; RNA was isolated
8 hours post transfection and assayed for expression of IFN genes),
the ex vivo pDCs significantly upregulated IFNa2 (except the TT
subject), IFNb1, IL-28A (IFNl2), IL-28B (IFNl3; except the CT
subject) and IL-29 (IFNl1) compared to the X-region RNA
(Figure 7A). Due to the importance of the IL-28B (IFNl3) SNP to
HCV clearance, we selected subjects with each of the 3 possible
genotypes to test. The subjects with the favorable CC genotype
had over 100 fold more robust responses to the pU/UC RNA than
the subjects with the CT or TT genotype. Additionally, the CC
genotype subjects’ gene expression levels were significantly higher
than the non-CC genotype subjects’ gene expression level in all
cases except IL28B/IFNl3 (IFNa2 p,0.05, IFNb1 p,0.01,
IL28A/IFNl2 p,0.01, IL28B/IFNl3 n.s., IL29/IFNl1 p,0.01;
Figure 7B). While the TT genotype had the least robust response,
the IFN genes were still significantly upregulated compared to the
X-region RNA control. One of the reasons for the difference
between the cell line Interferon levels and the non-CC ex vivo cell
Interferon levels may be that the cell line has both of the
‘‘favorable’’ genotypes for IL-28B/IFNl3 (rs12979860; CC)
[14,15] and RIG-I (rs10813831; AA) [18] while the non-CC
subjects have the ‘‘unfavorable’’ TT or CT for the IL-28B/IFNl3
SNP and AA or GG for the RIG-I SNP. Though the AA RIG-I
genotype is considered to be ‘‘favorable’’, the presence of that
favorable allele was not enough to overcome the ‘‘unfavorable’’
IL-28B/IFNl3 SNP. These data confirm that ex vivo pDCs are
capable of responding robustly to HCV RNA with Type I and III
Interferon production.
The supernatants from these cells were assayed for IFNa and
IL-29 (IFNl1) by ELISA (Figure S5A and S5B). Each subject’s
pDCs had more IFN present in the pU/UC-transfected condition
compared to the X-region-transfected condition. Conditioned
media from the transfected primary ex vivo pDCs were used to treat
infected Huh7.5.1 cells in the same manner as previously
described for the pDC-GEN2.2 CM. The pU/UC-transfected
CM from the CC subjects (but not the non-CC subjects) controlled
virus better than X-region-transfected CM from those same
subjects (Figure S5C).
Discussion
Dendritic cells play a critical role as innate pathogen sensors
[29]. Although they constitute only 0.2% to 0.8% of peripheral
leukocytes in healthy subjects, pDCs have been found to produce
over 95% of Type I IFNs by PBMCs in response to many viruses
[29]. HCV represents the most common blood-borne viral
infection for which there is no vaccine [6]; acute infection is
followed by development of viral persistence in the majority of
subjects. In this study, we comprehensively characterized the
response to transfected hepatitis C viral PAMP using the pDC cell
line GEN2.2. As with any cell line, there were some differences
between the cell line and ex vivo cells. In keeping with prior reports
[30], we did not find freshly isolated human ex vivo pDCs to express
TLR3 (Figure S5); in contrast, the pDC cell line did express
TLR3. However, for the most part, the cell line resembled ex vivo
cells.
The current dogma is that TLR and not RLR signaling
predominate within the pDC population [5]. In this study, TLR
ligand stimulation of pDCs increased transcription of Type I and
III IFNs, as well as PRRs. These data suggest that TLR ligation
not only induces IFN, but also primes the cells for recognition of
additional viral stimuli. This type of priming has not been
thoroughly investigated for viruses although the presence of
bacterial products such as LPS have been shown to prime various
innate immune cells, primarily neutrophils [31] and macrophages
[32]. A feedback mechanism of TLR3 upregulation by Type I
IFNs to amplify the response to TLR3 ligands was previously
proposed [33]. It may also be the case that viral stimulation primes
pDCs for additional recognition and enhanced IFN production.
When we stimulated the cells with PEG-IFN-a2, we failed to
induce Type III IFNs, data that are consistent with a recent study
using primary human hepatocytes [27]. In accordance with prior
reports, we found that the cytosolic receptor RIG-I was IFN-
inducible [5]. We speculate that the induction of the IFN genes
Figure 6. Co-culture of JFH-1-infected Huh7.5.1 cells and pDC-GEN2.2 cells leads to the upregulation of IFN genes and viral control.
A) Huh7.5.1 cells were infected for 24 hours with JFH-1 and then resting pDC-GEN2.2 cells were added for 24 hours. mRNA from the CD45+ cells was
isolated and examined for IFN gene expression. Gene fold increase is shown for each gene after normalization to the reference gene GAPDH and the
uninfected condition. B) Huh7.5.1 cells were infected for 24 hours with JFH-1 and then pDC-GEN2.2 cells that had been mock transfected, transfected
with X-region RNA or pU/UC RNA for 8 hours were added for 4 days (5 days total infection). RNA was isolated and examined for JFH-1 copy number.
Normalized HCV copy number is shown where the infection control condition HCV copy number is set to 1 and other conditions are expressed as
normalized HCV copy number compared to infection control. Normalized HCV Copy Number = (Absolute copy number for condition/absolute copy
number for infection control) p values represent the Mann-Whitney result of the comparison. * p,0.05 ** p,0.01 *** p,0.001 # p#0.0001. Bars
represent the mean and error bars are +/2 SEM.
doi:10.1371/journal.ppat.1003316.g006
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may lead to an antiviral state within in vivo pDCs thus making
them resistant to HCV infection and prone to rapid clearance of
the virus within the pDCs themselves. This may explain why HCV
RNA is not consistently found within circulating pDCs from
HCV-infected patients.
The pDC cell line produced IFN in response to pU/UC RNA,
but not X-region RNA, with most genes peaking in expression at
8 hours, consistent with the known kinetics of IFN gene expression
[34]. Given that the pU/UC RNA was generated using an in vitro
transcription system, one potential concern was that the 59
triphosphate added by the T7 polymerase might artificially induce
IFN responses. However, since the X-region RNA was made in
the same way (and thus had the same triphosphate), but failed to
induce IFN production (Figure S2), we felt confident that the
gene and protein expression levels that we observed were due to
pU/UC RNA-specific features.
In this study, transfection was used to introduce HCV RNA into
the pDC-GEN2.2 cells. Previous work has demonstrated that
pDCs can sense HCV and respond with IFNa production in an in
vitro system using Huh7.5.1 c2 cells and JFH-1 requiring cell-to-cell
contact [13]. Chisari’s group also showed that receptor-mediated
entry of the virus into the pDCs was not required to induce IFN
production [13]. This latter study provides rationale for using
transfection to mimic the non-receptor mediated transfer of RNA
from hepatocytes to pDCs. We found that HCV PAMP
transfection of pDCs induced an antiviral effect when co-cultured
with infected hepatocytes. In keeping with and extending
Takahashi’s study, we found that co-culture with infected
Huh7.5.1 induced transcriptional upregulation of Type I and III
IFNs. There are a number of means by which pDCs could sense in
vivo infected hepatocytes, including encounter of viral RNA in
debris from infected cells killed by immune mechanisms, such as
natural killer cells, or from endocytosed virions. Transfection acts
as a laboratory tool to imitate viral RNA transfer in vivo.
Viral control in our replication model system related to the
conditioned media (CM) from pU/UC RNA-transfected pDCs
was partially mediated by Type III IFNs. This is in agreement with
previous reports that IFNls can control HCV in vitro [35]. We also
demonstrated that STAT1 and IRF9 were upregulated by the
addition of pU/UC-transfected CM, but not X-region-transfected
CM, which implicate a role for IFNs in mediating the viral control
within the infected hepatocytes. At the same concentrations as
detected in the CM, Type III IFNs were able to control HCV
replication. Both IL-28A (IFNl2) and IL-29 (IFNl1) at higher
concentrations (100 ng/ml) have been shown to significantly
reduce HCV replication with the same efficacy and comparable to
IFNa [36]. In light of prior work indicating that viral transcription
is not required for RIG-I activation [37], our collective data
suggest an IFN-mediated mechanism that provides inhibition of
HCV replication during the initial stages of infection [35,38].
Human pDC sense conserved regions of HCV RNA, resulting in
the upregulation of the cytosolic RIG-I- helicase, ISGs, and robust
production of Type III IFNs that mediate antiviral activity in
HCV-infected hepatocytes.
Figure 7. Ex vivo pDCs upregulate Type I and III Interferon
genes in response to the HCV PAMP. A) Gene expression changes
in ex vivo pDCs after HCV PAMP RNA stimulation. Top: subjects with the
CC IL28B/IFNl3 genotype (2 subjects IL28A/IFNl2, IL28B/IFNl3, IL29/
IFNl1 and IFNb1; 1 subject IFNa2; RIG-I SNPs GG and GA); middle: CT
IL28B/IFNl3 genotype (1 subject, RIG-I SNP AA); Bottom: TT IL28B/IFNl3
genotype (1 subject RIG-I SNP GG). Top graph is combined data from 2
independent experiments while middle and bottom graphs are data
from a single independent experiment each. B) Same gene expression
data as in A graphed together. Compared to the non-CC genotypes, the
CC subjects had significantly more IFN mRNA. p values are the Wilcoxon
signed rank result for (A) each gene compared to the X-region
stimulation (dashed line) from the same gene, and (B) each gene CC
genotype compared to each gene non-CC genotype. * p,0.05
** p,0.01 *** p,0.001 # p#0.0001. Bars represent the mean and
error bars are +/2 SEM.
doi:10.1371/journal.ppat.1003316.g007
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The current observations also help shed light on the puzzling
lack of association between IL-28B/IFNl3 SNPs and hepatic
expression of Type III IFNs reported in the literature [7]. Our
data using both a cell line and freshly isolated ex vivo cells suggest
that pDCs sensing HCV RNA produce different levels of IFN,
perhaps indicating a functional role of the polymorphisms in the
IL28B/IFNl3 gene locus. Hepatic mRNA (in prior studies) would
have been derived predominantly from hepatocytes, whereas the
main cellular sources of Type III IFNs are pDCs. Interestingly,
pDCs derived from subjects with the favorable CC genotype also
demonstrate significantly more robust Type I IFN transcription
following HCV PAMP stimulation that may be the result of an
amplification feedback loop or modification of transcriptional
factors. Clearly, further work is warranted to understand the
mechanisms of how Type I and III IFNs might be co-regulated.
Induction of RIG-I mediated responses by the use of synthetic
agonists may have implications for novel therapeutic approaches
for this common infection. Moreover, mechanisms that antagonize
RIG-I-mediated stimulation of IFN warrant further investigation




Patients were recruited and written informed consent was
obtained using COMIRB approved protocol # 08-0364 from the
Denver Metro area.
Cell culture
GEN2.2 cell line was grown on Huh7.5.1 cells in either DMEM
with 10% Human Serum+1X Pen/strep+1X NEAA (Non-
essential Amino Acids) or RPMI with 10% FBS+1X Gentamycin.
No differences in the functionality of the cells were seen based on
media condition (Data not shown). Briefly, Huh7.5.1 cells were
plated and allowed to grow until 90% confluency then the
GEN2.2 cells were added. For experiments, the non-adherent
fraction of the culture was used. These cells were over 95%
BDCA-2+ and CD45+ thus indicating that the feeder line was not
included in these experiments.
Flow cytometry
Surface stain. Cells were washed with FACS wash (PBS with
0.016% sodium azide, 0.6% BSA). Cells were then resuspended in
FACS wash containing fluorescently labeled antibodies (BDCA-2,
BDCA-3, BDCA-4 and BDCA-1: Miltenyi Biotech. Lineage
cocktail, CD123, HLA-DR, CD86, CD80, CD83, CD209,
CD45, CD44, CD119, TLR9, CD93w: BD Biosciences. CD11c,
and TLR3: eBiosciences. IFNAR1: R&D Systems) and incubated
at 4C for 30 minutes. Cells were then washed twice in FACS wash
and resuspended in 2% PFA in PBS for 20 min. Cells were
acquired within 24 hours on BD FACSCanto II. Data was
analyzed using FlowJo software. Intracellular stains: Cells were
stained for surface antigens as described above until second wash
after antibody incubation. Cells were then resuspended in BD
Perm Buffer III (BD 558050) for 30 minutes then pelleted and
resuspended with intracellular antibodies in BD Perm Buffer III
for 30 minutes. Cells were then pelleted and resuspended in 2%
PFA for 20 min. Cells were acquired within 24 hours on BD
FACSCanto II. Data was analyzed using FlowJo software.
Fluorescent microscopy
Cells were fixed in 4% PFA for 30 minutes. Cells were then
washed in DPBS and resuspended in blocking buffer (3% BSA,
10% FBS, 0.3% Triton X-100 in DPBS) for 30 minutes at room
temperature. Cells were then washed in DPBS and resuspended in
Phalloidin conjugated to AlexaFluor 488 (Invitrogen A12379) in
Binding Buffer (10% FBS, 0.3% Triton X-100 in DPBS) for
30 minutes in the dark at room temperature. Cells were then
washed in DPBS and resuspended in DPBS. Cells were cytospun
on the slide by using adding the cell suspension to a cytofunnel and
spun at 1000 rpm for 5 min. The slide was allowed to dry at room
temperature in the dark. Mounting media containing DAPI
(Vector Labs H-1200) was added to the slides and covered with a
coverslips and sealed. Slides were viewed on a Leica DM5000B
with a Leica DFC350FX camera. The objective lenses were Leica
506507 (10X/0.30 NA), Leica 506506 (20X/0.50 NA) and Leica
506145 (40X/0.75 NA). Images were taken at room temperature
(23uC) and acquired using Leica FW400 software. Images were
not adjusted or modified after image capture.
TLR and IFNa stimulation
Cells were plated in a 24 well low-adherence plate (Costar 3473)
at a concentration of 16106 cells in 1 mL per well. TLR ligands,
IFNa or media were added: either alone or in combination: Poly
I:C [100 mg/mL, Sigma P0913], ODN 2216 CpG [250 mM,
Invivogen tlrl-hodna], Loxiribine [1 mM, Invivogen tlrl-lox],
PEG-IFNa [100 ng/mL]. The cells were incubated at 37C, 5%
CO2 for 6 hours at which time RNA was isolated using RNeasy
Mini kit (Qiagen, 74106) with the Qiashredder option (Qiagen,
79656). RNA was quantified using a Nanodrop microspectometer.
1 mg of RNA was used to make cDNA using Quantitect RT kit
(Qiagen, 205313). qRT-PCR was performed using SYBR Green
primers and master mix from Qiagen and run on a StepOnePlus
qPCR machine from Applied Biosystems. Data was analyzed by
the DDCT method. All primers used in the qRT-PCR assays were
purchased from Qiagen.
HCV PAMP preparation
pU/UC and X-region plasmids were kindly provided by Dr.
Michael Gale’s lab. The plasmids were amplified using PCR (X-
region Forward 59-TAATACGACTCACTATAGGTGGCTC-
CATCTTAGCCCTA-39 X-region Reverse 59-ACTTGATCTG-
CAGAGAGGCCAGTATCA-39 HCV pU/UC Forward 59-
TAATACGACTCACTATAGGCCATCCTGTTTTTTTCCC-
39 HCV pU/UC Reverse 59-AAAGGAAAGAAAAG-
GAAAAAAAGAGG-39) with a high fidelity polymerase (Invitro-
gen 11304-011). The PCR products were separated with
electrophoresis on an (1%) agarose gel. The bands of interest
were extracted from the gel (Gel extraction kit, Qiagen 28704) and
transcribed in vitro (Applied Biosystems AM1354M). The final
product was quantified using a Nanodrop microspectometer. For
removal of the 59 Phosphate groups, the HCV PAMP RNA was
treated with Antarctic phosphatases (New England Biolabs,
M0289) as per manufacturer’s instructions. The enzyme was
deactivated for 5 min at 65C. This RNA was then used as
described for the untreated HCV PAMP (see below).
HCV PAMP stimulation
Cells were plated in a 24 well low-adherence plate at a
concentration of 16106 cells in 1 mL per well. 1 mg of pU/UC, or
X-region RNA or 1 mL water (mock) were transfected (Mirus
2250) for 2, 4, 8 or 24 hours at 37C, 5% CO2. 1 mg of RNA was
used because 1 mg of HCV PAMP RNA was used by Dr. Gale’s
group in their original study of the immunogenic capacity of these
RNAs [16]. RNA was isolated, cDNA was generated and qRT-
PCR was run and analyzed as described for TLR stimulation.
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Supernatants were also collected at 2, 4, 8 or 24 hours post-
transfection.
siRNA knockdown
Cells were plated in a 24 well low-adherence plate in 500 mL/
16106 cells serum-free Accell Delivery Media (Dharmacon # B-
005000). siRNA was then added to a final concentration of
750 nM. Cells were incubated for 48 hours at 37C, 5% CO2.
Accell Delivery Media+10% Heat-inactivated FBS (500 mL/
16106 cells) was added to the wells. Cells were incubated for an
additional 24 hours and then stimulated as described above.
DDX58 (RIG-I) siRNA (Smart Pool; E-012511-00) and scrambled
siRNA (Non-targeting control; D-001910-10) were obtained from
Fisher Scientific.
ELISAs
ELISA kits for IFNa (PBL Interferon Source, 41105), IFNb
(PBL Interferon Source, 41410), IL-28A/IFNl2 (RayBio, ELH-
IL28A-001) and IL-29/IFNl1 (eBiosciences, 88-7296) were used
as per the manufacturer’s instructions. All samples used at either a
1:1 or 1:10 dilution and were incubated overnight at 4C.
Western blots
Cell lysates were prepared by stimulating cells as described
above. Cells were harvested on ice and washed twice with cold
PBS. Cells were then lysed with a Modified RIPA buffer (Tris-HCl
50 mM, 1% NP-40, 0.25% Na-deoxycholate, NaCl 150 mM,
EDTA 1 mM pH 7.4) with 1X protease inhibitors (Roche 11 836
170 001) and 1X phophatase inhibitors (Fisher Scientific, PI-
78420). After 30 minutes of agitation at 4C, cell lysates were
centrifuged and pellets were discarded. Protein levels were assayed
using a BCA assay (Fisher, PI-23221 and PI-23224) as per
manufacturer’s instructions. Samples were separated using SDS-
PAGE on Mini-protean TGX Any kD gels (Bio-rad, 456-9033)
and transferred onto a nitrocellulose membrane using a wet
transfer system. Membranes were blocked for 1 hour with 5%
milk in TBST or PBST, washed, and proteins were analyzed by
immunoblotting with standard methods using antibodies specific
to RIG-I (Enzo Lifesciences), MDA5 (Cell Signaling Technology),
MyD88 (Cell Signaling Technology), IL-28B/IFNl3 (R&D
Systems), RNase L (Thermo Scientific), TRIF (Cell Signaling
Technology), tubulin (Sigma), and GAPDH (Abcam). Secondary
antibodies conjugated to HRP were obtained from Jackson
ImmunoResearch and Cell Signaling Technology, and immuno-
reactive bands were detected with either the Immuno-Star HRP
Substrate kit (Bio-Rad, 170-5040) or the Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare). Densitom-
etry was performed using ImageJ (NIH), and proteins of interest
were normalized to a reference protein (Tubulin or GAPDH).
RNA gels
Whole RNA was isolated from HCV PAMP stimulated cells as
described above. RNA was run on a 1% agarose formaldehyde gel
with Ethidium bromide. Gel was visualized via UV.
Viral control assays
Huh7.5.1 cells (kindly provided by Frank Chisari, Scripps) were
plated in a 24 well plate at a concentration of .1256106 cells per
well in 1 mL media overnight. The cells were then infected with
JFH-1 at an MOI (multiplicity of infection) of 0.01. Twenty-four
hours following infection, the supernatants generated from the
HCV PAMP transfection (either Mock (negative) transfection, X-
region or pU/UC) were added at various dilutions. Five days post-
infection the supernatants were aspirated and RNA was isolated as
previously described. HCV copy number qRT-PCR was per-
formed using JFH-1 primers (JFH-1 Forward 59-CGA-
CACTCCGCCATGAATCACT-39 and JFH-1 Reverse 59-
CACTCGCAAGCGCCCTATCA-39) and TaqMan TAMRA
probe (59-6FAMAGGCCTTTCGCAACCCAACGCTACT-
TAMRA-39). The copy number was determined using a standard
curve. Using the infection control condition absolute HCV copy
number all other conditions’ copy numbers were normalized for
that particular experiment. The following formula was used to
determine Normalized HCV Copy Number: Normalized HCV
Copy Number = (Absolute copy number for condition/absolute
copy number for infection control). A blocking antibody against
IL-28B/IL-29 (IFNl3/IFNl1) or an isotype control antibody
were obtained from R&D Systems (10 mg/mL, MAB15981,
MAB003) or the recombinant Vaccinia protein B18R from
eBioscience (0.1 mg/mL; 14-8185-62) and added to the superna-
tants at 24 hours post-infection and the experiment was performed
as described. Recombinant Interferon proteins (IL-28A/IFNl2,
PeproTech, 300-02K: 1500 pg/mL; IL-29/IFNl1 PeproTech,
300-02L: 500 pg/mL; IL-28B/IFNl3, R&D Systems, 5259-IL-
025: 10 pg/mL) were added to the infected Huh7.5.1 cultures
24 hours post-infection and the experiment was performed as
described above. For the JAK/STAT pathway gene expression
arrays (Applied Biosystems, 4414156) and validation Huh7.5.1
cells were plated, infected and treated with pDC supernatants as
described above. Sixteen hours after the addition of the
supernatants, the cells were harvested for RNA as previously
described. cDNA was made and the gene expression array plates
were run as per manufacturer’s instructions or individual genes
were examined by qRT-PCR as described above. For co-culture
experiments, Huh7.5.1 cells were plated overnight and infected as
described above. The non-transfected pDC-GEN2.2 cells were
added 24 hours post-infection. Cells were co-cultured for 24 hours
and then the non-adherent fraction was collected for qRT-PCR
analysis. This fraction was examined for BDCA-2 expression and
98+% were BDCA-2+ indicating little to no contamination of the
Huh7.5.1 cells. For the co-culture experiments with the transfected
pDC-GEN2.2, Huh7.5.1 cells were plated and infected as
described above. Twenty-four hours post-infection, pDC-
GEN2.2 cells were transfected with HCV PAMP RNA as
described previously in the methods (8 hour transfection) and
added to infected Huh7.5.1 cells. As described above for pure
Huh7.5.1 cultures, the cultures were examined five days post-
infection for HCV copy number by qRT-PCR.
pDC isolation from whole blood
Patients were recruited and consented using COMIRB
approved protocol # 08-0364 from the Denver Metro area.
PBMCs from normal, healthy patients were screened for pDC
percentage of .0.25% of total PBMCs using Lineagenegative, HLA-
DR+, BDCA-2+ and BDCA-4+. Patient cells were also genotyped
for IL28B and RIG-I SNPs (rs12979860 and rs10813831,
respectively). Patients were leukopheresed and pDCs were
immediately isolated using Miltenyi’s Diamond Plasmacytoid
Dendritic Cell Isolation Kit II (Miltenyi Biotech, 130-097-240)
and characterized using flow cytometry and fluorescent micros-
copy as described for the pDC cell line. Cells were then stimulated
in the exact same way as the pDC-GEN2.2 cell line with the HCV
PAMP RNA (1 mg of RNA was transfected into the cells, 8 hours
later RNA was isolated, 1 mg of RNA was used to make cDNA
and assayed for gene expression by qRT-PCR). Due to cell
number limitations, only a single time-point could be examined.
Eight hours was chosen since the pDC-GEN2.2 gene expression
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peaked at this time-point. ELISAs and viral control were
performed as described above for the pDC-GEN2.2 cell line.
Statistics
Statistics were performed using Graphpad Prism statistical
package. Student’s T-test was used for comparisons amongst
groups with more than 30 data points. Mann-Whitney non-
parametric test was used for comparisons amongst groups with less
than 30 data points. One sample t-tests or Mann-Whitney tests
were used to compare fold increases of stimulated conditions with
control conditions.
Supporting Information
Figure S1 IFNa2 has a relatively weak effect on IFN and
PRR induction, compared to either TLR or PAMP
stimulation. A) IFNa2 (100 ng/mL) had a modest effect on
most IFNs, failing to induce Type III IFNs. B) Of the PRR genes
tested, only RIG-I was upregulated by IFNa. p values are the
Wilcoxon signed rank result for the difference between the
IFNa condition and media alone condition (dashed line) for each
gene. Combined data for 5 independent experiments. * p,0.05
** p,0.01 *** p,0.001 # p#0.0001. Bars represent the mean
and error bars are +/2 SEM.
(TIF)
Figure S2 Induction of interferon genes by transfection
of the HCV PAMP or X-region control compared to the
mock transfection. A) Transfection of the pU/UC RNA into
the pDC cell line induces robust IFN gene expression when
compared to the mock transfected condition (dashed line). B)
Transfection of the X-region RNA (Negative Control) into the
pDC cell line induces low levels of IFN gene expression compared
to the mock transfected condition (dashed line). Combined data
from 5 independent experiments. Bars represent the mean and
error bars are +/2 SEM.
(TIF)
Figure S3 RNaseL is not upregulated during the pDC-
GEN2.2 response to the HCV PAMP. A) RNaseL mRNA
levels are not increased with pU/UC transfection nor are they
increased over time. B) RNA gel of whole RNA from mock, X-
region or pU/UC transfected pDC-GEN2.2 cells shows clear 28S
and 18S rRNA bands suggesting that RNaseL is not activated by
pU/UC transfection. C) Western blot of RNaseL in the pDC cell
line shows no change of protein levels with HCV PAMP
stimulation. D) Densitometry showed no differences amongst the
conditions. Data are combined from 3 independent experiments.
Gel and blot images are representative images of 3 independent
experiments. Bars represent the mean and error bars are +/2
SEM.
(TIF)
Figure S4 HCV PAMP stimulated conditioned media
upregulates IRF9 and STAT1 in Huh7.5.1 cells. The top
hits from the JAK/STAT PCR array were followed up by targeted
qRT-PCR. As in Table S1, RNA was harvested and assayed
16 hours after addition of CM to infected Huh7.5.1 cells. p values
are the Wilcoxon signed rank result for each gene compared to the
X-region CM treatment from the same gene. * p,0.05 ** p,0.01
*** p,0.001 # p#0.0001. Bars represent the mean and error bars
are +/2 SEM.
(TIF)
Figure S5 Ex vivo conditioned media (CM) has IFN
protein and controls viral replication. ELISA data from the
supernatants of HCV PAMP stimulated ex vivo pDCs for IFNa (A)
and IL-29/IFNl1 (B). C) Infected Huh7.5.1 cells were treated
with ex vivo CM as described for pDC-GEN2.2 CM and HCV
copy number was determined by qRT-PCR. Normalized HCV
copy number is shown where the infection control condition HCV
copy number is set to 1 and other conditions are expressed as
normalized HCV copy number compared to infection control.
Data is shown grouped by CC or non-CC genotype. Normalized
HCV Copy Number = (Absolute copy number for condition/
absolute copy number for infection control). p values are the
Wilcoxon signed rank result for between the X-region and pU/
UC CM conditions. Each graph for shows the total data from the
4 subjects assayed in Figure 6. * p,0.05 ** p,0.01 *** p,0.001
# p#0.0001. Bars represent the mean and error bars are +/2
SEM.
(TIF)
Figure S6 Isolated ex vivo pDCs are 95+% pure and
express classic pDC markers by flow cytometry. A)
Isolated ex vivo pDCs were HLA-DR+ BDCA-2+ CD123+
CD11c2 BDCA-12. B) Little contamination of CD56+ CD32
(Natural Killer cells), CD19+ (B cells) and CD14+ (monocytes) in
the pDC preparations. C) Isolated ex vivo pDCs express low levels
of co-stimulation markers CD80 and CD86 but highly expressed
CD44. D) Ex vivo pDCs express TLR9 but not TLR3.
(TIF)
Table S1 HCV PAMP stimulated conditioned media
upregulates the JAK/STAT pathway within hepatocytes.
HCV-infected Huh7.5.1 cells (24 hours of infection prior to CM
addition) were assayed 16 hours after the addition of Conditioned
Media from pU/UC or X-region stimulated pDC-GEN2.2 cells
by PCR array for JAK/STAT genes expression changes. Shown
are the genes that were differentially regulated in the cells treated
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Gene Name Fold change 
PIK3CD 0.50  
EPOR 0.50  
ERBB2 0.50  
18S 0.50  
STAT2 2.00  
SUMO1 2.01  
STAT3 2.01  
GUSB 2.01  
MAP2K4 2.01  
JUN 2.01  
AKT3 2.01  
PIK3CB 2.01  
HRAS 2.01  
PSMA3 2.01  
PIK3R1 2.02  
PIK3CA 2.02  
SP1 2.02  
EP300 2.02  
MYC 2.02  
SOS1 2.02  
FGF2 2.02  
PTPN6 2.02  
IFNAR1 2.02  
ELP2 2.03  
STAT5B 2.03  
THPO 2.03  
PTPN11 2.03  
JAK1 2.03  
UBC 2.03  
RAF1 2.04  
STAM 2.04  
MAP2K3 2.05  
PRLR 2.05  
JAK2 2.11  
IFNA2 4.92  
IFNA1 6.31  
IRF9 7.99  
STAT1 8.04  
